Loading...
THRN logo

Thorne HealthTech, Inc.NasdaqGS:THRN Stock Report

Market Cap US$550.6m
Share Price
n/a
US$8.6
n/aintrinsic discount
1Y128.5%
7D0.1%
1D
Portfolio Value
​
View

Thorne HealthTech, Inc.

NasdaqGS:THRN Stock Report

Market Cap: US$550.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Thorne HealthTech (THRN) Stock Overview

Thorne HealthTech, Inc., a science-driven wellness company, provides solutions and personalized approaches to health and wellness in the United States and internationally. More details

THRN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance4/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 56.7% below our estimate of its fair value

Earnings are forecast to grow 57.16% per year

Earnings grew by 548.7% over the past year

Risk Analysis

High level of non-cash earnings

Shareholders have been diluted in the past year

Volatile share price over the past 3 months


THRN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Thorne HealthTech, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Thorne HealthTech
Historical stock prices
Current Share PriceUS$10.19
52 Week HighUS$10.20
52 Week LowUS$3.41
Beta0.82
1 Month Change0.39%
3 Month Change93.36%
1 Year Change128.48%
3 Year Changen/a
5 Year Changen/a
Change since IPO34.97%

Recent News & Updates

Recent updates

Analysis Article • Aug 12

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Thorne HealthTech, Inc. ( NASDAQ:THRN ) defied analyst predictions to release its second-quarter results, which were...
Analysis Article • Jun 07

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

With a price-to-earnings (or "P/E") ratio of 25.5x Thorne HealthTech, Inc. ( NASDAQ:THRN ) may be sending very bearish...
Analysis Article • Dec 17

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...
Seeking Alpha • Sep 09

Thorne HealthTech Grows But Faces Macro Headwinds

Summary Thorne HealthTech went public in September 2021, raising approximately $70 million in a U.S. IPO. The company designs and sells wellness and nutraceutical products worldwide. THRN has produced revenue growth but faces inflationary pressures, the loss of a significant distributor in Europe and the stock may be fully valued here. I'm on Hold for THRN for the near term. A Quick Take On Thorne HealthTech Thorne HealthTech, Inc. (THRN) went public in September 2021, raising approximately $70 million in gross proceeds from an IPO that priced at $10.00 per share. The firm designs and sells wellness and nutraceutical products under its brands Thorne and Onegevity. Given the risks of continued inflationary pressures and a macroeconomic slowdown combined with a potentially fully valued stock at its current price of around $5.00 per share, I'm on Hold for THRN in the near term. Thorne HealthTech Overview New York, NY-based Thorne was founded to develop premium wellness products for consumers utilizing its Onegevity platform to discover and develop new products. The firm sells products directly and also has a product subscription program Management is headed by Chief Executive Officer Paul Jacobson, who has been with the firm since 2010 when he acquired Thorne Research and was previously co-founder of Onegevity Health, which was acquired by Thorne. THRN sells its products through a direct to consumer channel [DTC] as well as through online ecommerce sites such as Amazon, distributors and through connected health professionals. The company also gathers personalized testing data and has plans to use this information for additional services to practitioners. Thorne HealthTech's Market & Competition According to a 2021 market research report by Grand View Research, the global market for dietary supplements was an estimated $140.3 billion in 2020 and is forecast to reach $271 billion by 2028. This represents a forecast CAGR of 8.6% from 2021 to 2028. The main drivers for this expected growth are a growing consumer awareness of personal health and wellness products as well as increased R&D from product makers. Also, below is a chart showing the historical and projected future market size by ingredient for dietary supplements in the U.S.: U.S. Dietary Supplements Market (Grand View Research) Major competitive or other industry participants include: Nestle Health Science Metagenics Hims 23and Me Livongo Schrodinger SEMA4 Numerous other nutritional supplement companies Thorne HealthTech's Recent Financial Performance Total revenue by quarter has grown according to the following chart: 9 Quarter Total Revenue (Seeking Alpha) Gross profit by quarter has followed approximately the same trajectory as that of total revenue: 9 Quarter Gross Profit (Seeking Alpha) Selling, G&A expenses as a percentage of total revenue by quarter rose substantially in the most recent quarter: 9 Quarter Selling, G&A % Of Revenue (Seeking Alpha) Operating income by quarter has turned negative in Q2 2022: 9 Quarter Operating Income (Seeking Alpha) Earnings per share (Diluted) have turned into negative territory in Q2 2022: 9 Quarter Earnings Per Share (Seeking Alpha) (All data in above charts is GAAP) Since its IPO, THRN's stock price has fallen 38.4% vs. the U.S. S&P 500 index' drop of around 9.9%, as the chart below indicates: Stock Price Since IPO (Seeking Alpha) Valuation And Other Metrics For Thorne HealthTech Below is a table of relevant capitalization and valuation figures for the company: Measure [TTM] Amount Enterprise Value / Sales 1.31 Revenue Growth Rate 28.5% Net Income Margin 0.97 GAAP EBITDA % 1.8% Market Capitalization $267,930,000 Enterprise Value $272,780,000 Operating Cash Flow $1,190,000 Earnings Per Share (Fully Diluted) $0.04 (Source - Seeking Alpha) Below is an estimated DCF (Discounted Cash Flow) analysis of the firm's projected growth and earnings: Discounted Cash Flow - Thorne (GuruFocus) Assuming generous DCF parameters, the firm's shares would be valued at approximately $5.13 versus the current price of $5.01, indicating they are potentially currently fully valued, with the given earnings, growth and discount rate assumptions of the DCF. As a reference, a relevant partial public comparable would be larger firm Glanbia plc (GLAPF, GLAPY); shown below is a comparison of their primary valuation metrics: Metric Glanbia plc Thorne HealthTech Variance Enterprise Value / Sales 0.79 1.31 65.8% Revenue Growth Rate 23.7% 28.5% 20.3% Net Income Margin 5.4% 0.97 1689.7% Operating Cash Flow $104,990,000 $1,190,000 -98.9% (Source - Seeking Alpha) A full comparison of the two companies' performance metrics may be viewed here. Commentary On Thorne HealthTech In its last earnings call (Source - Seeking Alpha), covering Q2 2022's results, management highlighted improvements in its sales mix and the effect of increased prices and scale growth as offsets to inflationary pressures on its cost of sales. Notably, the firm's Pro and B2B sales channels produced strong growth year-over-year, excluding the loss of a distributor related to the conflict in Ukraine, which it estimates reduced Q2 revenue by "as much as $6.9 million."
Seeking Alpha • Aug 23

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Thorne HealthTech (NASDAQ:THRN) said its blood collection device OneDraw was certified in Japan as a medical device after being cleared by the Pharmaceutical and Medical Devices Agency (PMDA). "We appreciate the help from our partners in Japan because we believe this will create many additional opportunities to expand our relationships globally, while we continue to move forward on a similar regulatory pathway in the United States," said Thorne CEO Paul Jacobson. The company noted that OneDraw is already approved by the FDA as a class 2 medical device, and it has a European Conformity mark for supervised use by health-care professionals to collect blood samples to measure HbA1c for monitoring the long-term control of blood sugar (glucose) in diabetic individuals.
Seeking Alpha • Aug 09

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Thorne HealthTech press release (NASDAQ:THRN): Q2 Non-GAAP EPS of -$0.05 (vs. $0.22 Y/Y). Revenue of $56.1M (+30.8% Y/Y). FY22 guidance revised to net sales of $235M to $242M (vs. consensus of $247.13M) and EPS of of $0.36 to $0.39 (vs. consensus of $0.34). Shares -1.47% AH.
Seeking Alpha • Jun 05

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Nutraceutical companies will perform well during the next decade, even during a recession. DIY health trends are on the rise. Thorne HealthTech is well-positioned to benefit from these trends.
Analysis Article • Mar 23

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Thorne HealthTech, Inc.'s ( NASDAQ:THRN ) strong earnings report was rewarded with a positive stock price move. We have...
Seeking Alpha • Jan 11

Thorne HealthTech: Good Potential At A Low Price

The market oversold Thorne shares. The company is growing at double-digit rates. It has strong positioning and enormous market potential. If marketing efficiency remains the same in the coming years, revenue will grow exponentially. This scenario is highly likely because the indicator is increasing. Despite the stage of aggressive growth, Thorne is already a profitable company. We expect the company to continue growing and improve profitability. The company is trading at a significant discount to its fair market value. PEG ratio is less than 1.

Shareholder Returns

THRNUS Personal ProductsUS Market
7D0.1%-2.1%1.4%
1Y128.5%-16.2%25.7%

Return vs Industry: THRN exceeded the US Personal Products industry which returned -31.9% over the past year.

Return vs Market: THRN exceeded the US Market which returned 14.1% over the past year.

Price Volatility

Is THRN's price volatile compared to industry and market?
THRN volatility
THRN Average Weekly Movement12.1%
Personal Products Industry Average Movement8.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: THRN's share price has been volatile over the past 3 months.

Volatility Over Time: THRN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1984544Paul Jacobsonwww.thorne.com

Thorne HealthTech, Inc., a science-driven wellness company, provides solutions and personalized approaches to health and wellness in the United States and internationally. It offers various health tests, such as sleep, stress, weight management, gut health, heavy metals, biological age, and other health tests that generate molecular portraits for its customers, as well as develops nutritional supplements and offers wellness education solutions. The company uses the Onegevity platform to map, integrate, and understand the biological features that describe the state of an individual’s health, as well as provide actionable insights and personalized data, products, and services that help individuals to take a proactive approach to enhance and maintain their health.

Thorne HealthTech, Inc. Fundamentals Summary

How do Thorne HealthTech's earnings and revenue compare to its market cap?
THRN fundamental statistics
Market capUS$550.63m
Earnings (TTM)US$20.33m
Revenue (TTM)US$258.01m
27.1x
P/E Ratio
2.1x
P/S Ratio

Is THRN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
THRN income statement (TTM)
RevenueUS$258.01m
Cost of RevenueUS$127.58m
Gross ProfitUS$130.43m
Other ExpensesUS$110.10m
EarningsUS$20.33m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.38
Gross Margin50.55%
Net Profit Margin7.88%
Debt/Equity Ratio16.1%

How did THRN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/18 08:47
End of Day Share Price 2023/10/13 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Thorne HealthTech, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bryan SpillaneBofA Global Research
Susan AndersonCanaccord Genuity
Elizabeth AndersonEvercore ISI